Praluzatamab Biosimilar – Anti-ALCAM, CD166 mAb – Research Grade

Description of Praluzatamab Biosimilar - Anti-ALCAM, CD166 mAb - Research Grade

Introduction to Praluzatamab Biosimilar

Praluzatamab Biosimilar, also known as Anti-ALCAM or CD166 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Praluzatamab. This biosimilar has been designed to target the protein ALCAM (Activated Leukocyte Cell Adhesion Molecule), which is also known as CD166. ALCAM is a transmembrane protein that is involved in cell adhesion and plays a crucial role in various cellular processes, including cell migration, proliferation, and differentiation. Praluzatamab Biosimilar has been developed as a research grade antibody and has the potential to be used as a therapeutic agent in the treatment of various diseases.

Structure of Praluzatamab Biosimilar

Praluzatamab Biosimilar is a recombinant humanized monoclonal antibody that has been produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the target protein ALCAM, while the constant regions provide stability and effector functions.

The amino acid sequence of Praluzatamab Biosimilar is highly homologous to the therapeutic antibody Praluzatamab, with a sequence identity of over 95%. This ensures that the biosimilar has similar binding properties and efficacy as the original antibody.

Mechanism of Action

Praluzatamab Biosimilar exerts its therapeutic effect by binding to ALCAM on the surface of cells. This binding prevents ALCAM from interacting with its natural ligand, resulting in the inhibition of ALCAM-mediated cell adhesion and signaling pathways. This, in turn, leads to the suppression of cellular processes such as proliferation and migration, which are important for the growth and spread of cancer cells.

Moreover, Praluzatamab Biosimilar also has the potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against ALCAM-expressing cells. This means that the biosimilar can activate the immune system to target and destroy cancer cells, further enhancing its therapeutic effect.

Applications of Praluzatamab Biosimilar

Praluzatamab Biosimilar has shown promising results in preclinical studies and has the potential to be used as a therapeutic agent for various diseases. It has been primarily studied in the treatment of solid tumors, including breast, lung, and colorectal cancers, which are known to overexpress ALCAM. The biosimilar has also shown efficacy in targeting cancer stem cells, which are responsible for tumor growth and recurrence.

In addition to cancer, Praluzatamab Biosimilar has also been studied for its potential in treating inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. ALCAM has been found to play a role in the pathogenesis of these diseases, making it a potential therapeutic target for Praluzatamab Biosimilar.

Conclusion

In conclusion, Praluzatamab Biosimilar is a promising research grade antibody that has been designed to target the protein ALCAM. Its highly homologous structure to the therapeutic antibody Praluzatamab and its ability to inhibit ALCAM-mediated cellular processes make it a potential therapeutic agent for various diseases, particularly cancer. Further clinical studies are needed to fully evaluate the efficacy and safety of Praluzatamab Biosimilar, but it has the potential to be a valuable addition to the arsenal of anti- cancer therapeutics.